5’-Ectonucleotidase (CD73) inhibitors: a patent review (2021-present)

Expert Opinion on Therapeutic Patents · Published 2026-03-05 · DOI 10.1080/13543776.2026.2638344

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1080/13543776.2026.2638344

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Sirtuin modulators: a review of patents from 2020 to 2024 · Expert Opinion on Therapeutic Patents · 2025 · Same journal
• A patent review of Mpro protease inhibitors for the treatment of COVID-19 infections (2020 – present) · Expert Opinion on Therapeutic Patents · 2025 · Same journal
• Therapeutic applications of benzoxaborole compounds: a patent and literature analysis (2019–2024) · Expert Opinion on Therapeutic Patents · 2025 · Same journal
• An updated patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2020–2025) · Expert Opinion on Therapeutic Patents · 2026 · Same journal
• PCSK9 inhibitors: an updated patent review 2024–2025 · Expert Opinion on Therapeutic Patents · 2026 · Same journal
• Topoisomerase II inhibitors in oncology: an updated patent review (2016-present) · Expert Opinion on Therapeutic Patents · 2025 · Same journal
• Recent advances in the discovery of PKMYT1-targeting drugs: a patent review (2021–2025) · Expert Opinion on Therapeutic Patents · 2026 · Same journal
• Implementation and outcomes of China’s drug patent linkage system: lessons from international experience · Expert Opinion on Therapeutic Patents · 2025 · Same journal
• An updated patent review of acetylcholinesterase inhibitors for the treatment of Alzheimer’s disease (2021–present) · Expert Opinion on Therapeutic Patents · 2025 · Same journal
• Insights and trends in development of TEAD–YAP/TAZ inhibitors: a review of PCT patents (2022 to June 2025) · Expert Opinion on Therapeutic Patents · 2025 · Same journal